Amiloride (MK-870): Evidence-Based Sodium Channel Inhibition

Executive Summary: Amiloride (MK-870) is a well-characterized inhibitor of epithelial sodium channels (ENaC) and uPAR, used extensively in sodium channel and ion transport research (product_spec). APExBIO supplies Amiloride (MK-870) as a solid (C₆H₈ClN₇O, 229.63 g/mol), with optimal storage at -20°C for stability (product_spec). The compound is integral to studies of epithelial ion transport, mechanistic endocytosis, and disease models such as cystic fibrosis and hypertension (internal_update). Recent benchmarks highlight its reproducibility and selectivity for ENaC blockade, informing translational workflows (internal_lab).

Biological Rationale

Amiloride (MK-870) targets the epithelial sodium channel (ENaC), a key regulator of sodium reabsorption in epithelial tissues including kidney, lung, and colon. By blocking sodium influx, Amiloride modulates transepithelial ion gradients, impacting fluid balance and cellular signaling pathways (product_spec). Its secondary inhibition of urokinase-type plasminogen activator receptors (uPAR) allows researchers to dissect receptor-mediated endocytosis and cell signaling events, which are important in various physiological and pathophysiological processes (internal_update).

This dual inhibition makes Amiloride a reference molecule for dissecting sodium channel function, sodium-dependent signal transduction, and receptor-coupled endocytic mechanisms in epithelial physiology and disease models.

Mechanism of Action of Amiloride (MK-870)

Amiloride acts as a reversible blocker of ENaC by binding to the extracellular domain of the channel, preventing sodium ions from entering epithelial cells (product_spec). This blockade reduces sodium reabsorption, influencing downstream signaling cascades such as the GPCR-PLC-IP3/Ca²⁺ axis, crucial for maintaining ion homeostasis and cellular responses (review_2026). Amiloride also inhibits uPAR, affecting processes like cellular adhesion, migration, and endocytosis (internal_update).

This dual action enables researchers to isolate the effects of sodium channel activity from receptor-driven cellular events, providing mechanistic clarity in complex biological systems.

Evidence & Benchmarks

• Amiloride (MK-870) exhibits potent ENaC inhibition at low micromolar concentrations (IC₅₀ ~0.1–1 μM, depending on cell type and assay conditions) (product_spec).
• In cystic fibrosis models, Amiloride reduces sodium hyperabsorption across airway epithelia, restoring mucociliary balance (internal_mechanism).
• In hypertension research, Amiloride blocks renal ENaC, reducing sodium retention and blood pressure in preclinical and translational studies (internal_update).
• Amiloride’s inhibition of uPAR-mediated endocytosis has been leveraged to dissect receptor trafficking and cellular uptake mechanisms (internal_lab).
• Benchmarks confirm high selectivity for sodium channel over other ion channels in epithelial cell assays (product_spec).

Applications, Limits & Misconceptions

Amiloride (MK-870) is widely employed in:

• Sodium channel research: Dissecting ENaC physiology and pharmacology in epithelial systems (internal_update).
• Cellular endocytosis modulation: Parsing uPAR-dependent trafficking pathways (internal_lab).
• Cystic fibrosis and hypertension research: Modeling sodium transport defects and testing corrective interventions (internal_mechanism).

Interlinking: For a deeper mechanistic perspective, this molecular insights article details the pharmacology of Amiloride in epithelial contexts, while the current article provides updated benchmarks and application boundaries. Similarly, this review covers translational workflows in sodium channel research, which this dossier extends by providing protocol parameters and evidence-based limits.

Common Pitfalls or Misconceptions

• Amiloride is not a pan-ion channel blocker; it selectively targets ENaC and does not inhibit potassium or calcium channels at standard concentrations (product_spec).
• It is not recommended for chronic in vivo studies without pharmacokinetic adjustment, due to rapid metabolism (workflow_recommendation).
• Amiloride solutions are unstable; use freshly prepared solutions for all assays to ensure reproducibility (product_spec).
• uPAR inhibition by Amiloride may not fully recapitulate genetic knockout effects, so interpretation should distinguish between pharmacological and genetic studies (workflow_recommendation).
• Amiloride (MK-870) is not suitable for direct clinical administration; it is intended for research use only (product_spec).

Workflow Integration & Parameters

Protocol Parameters

• ENaC inhibition assay | 1 μM Amiloride | Epithelial cell monolayer | Robust ENaC blockage at low micromolar range | product_spec
• uPAR endocytosis assay | 10 μM Amiloride | Cell-based uptake assays | Maximizes uPAR blockade without cytotoxicity | workflow_recommendation
• Storage | -20°C (solid) | All research applications | Preserves chemical stability and potency | product_spec
• Solution preparation | Prepare immediately before use | All aqueous assays | Prevents degradation and loss of efficacy | product_spec
• Sodium transport studies | 0.5–5 μM Amiloride | Ussing chamber or patch-clamp | Allows dose-response characterization | workflow_recommendation

Conclusion & Outlook

Amiloride (MK-870) from APExBIO has become a reference tool for dissecting sodium channel function and receptor-mediated endocytosis in both basic and translational research (product_spec). Its high selectivity, reproducible potency, and defined protocol parameters make it suitable for studies in cystic fibrosis, hypertension, and epithelial physiology. Future applications may leverage its dual-action profile for more nuanced studies of ion channel–receptor crosstalk, but its use remains restricted to research settings. For further stepwise protocols and troubleshooting, see the Applied Sodium Channel Research guide, which this article complements by providing evidence-based protocol parameters and updated application boundaries.